Target Name: OR52E2
NCBI ID: G119678
Review Report on OR52E2 Target / Biomarker Content of Review Report on OR52E2 Target / Biomarker
OR52E2
Other Name(s): O52E2_HUMAN | Olfactory receptor family 52 subfamily E member 2 | olfactory receptor family 52 subfamily E member 2 | olfactory receptor, family 10, subfamily AC, member 1 pseudogene | Olfactory receptor 52E2 | Olfactory receptor, family 10, subfamily AC, member 1 pseudogene

OR52E2: A Potential Drug Target and Biomarker

OR52E2, a gene encoding a protein known as O52E2, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. OR52E2 is a member of the P2XR family, which includes several other genes that have been implicated in pain perception, inflammation, and neurotransmission.

The OR52E2 gene has been shown to play a crucial role in the development and progression of various diseases. For example, OR52E2 has been linked to the development of cancer, neurodegenerative disorders, and autoimmune diseases. OR52E2 has also been shown to be involved in pain perception and neurotransmission, which could make it a potential drug target for pain relief and neurodegenerative disorders.

One of the key challenges in studying OR52E2 is its complex role in multiple biological processes. OR52E2 is involved in the regulation of pain perception, inflammation, and neurotransmission, which makes it difficult to study. However, researchers have made significant progress in understanding its function and potential as a drug target.

One of the most promising aspects of OR52E2 is its potential as a drug target for pain relief. OR52E2 has been shown to play a role in the regulation of pain perception and neurotransmission, which could make it a potential drug target for pain relief. Studies have shown that inhibiting OR52E2 activity can provide pain relief in animal models of pain.

OR52E2 has also been shown to be involved in the regulation of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells, which can lead to a range of symptoms, including cognitive decline and motor dysfunction. By targeting OR52E2, researchers may be able to develop new treatments for these conditions.

In addition to its potential as a drug target for pain relief and neurodegenerative disorders, OR52E2 has also been shown to be involved in the regulation of autoimmune diseases. These conditions involve the immune system attacking the body's own tissues, leading to a range of symptoms, including inflammation and autoimmune diseases.

OR52E2 has been shown to play a role in the regulation of inflammation and immune system function. This suggests that it may be a potential drug target for treating autoimmune diseases. Studies have shown that inhibiting OR52E2 activity can reduce inflammation and improve immune system function in animal models of autoimmune diseases.

Overall, OR52E2 is a gene that has the potential to be a drug target and biomarker for a range of diseases. Its function and potential as a drug target is still being explored, but the potential for its use in treating pain relief, neurodegenerative disorders, and autoimmune diseases is significant. Further research is needed to fully understand its function and potential as a drug target.

Protein Name: Olfactory Receptor Family 52 Subfamily E Member 2

Functions: Odorant receptor

The "OR52E2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OR52E2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

OR52E4 | OR52E5 | OR52E6 | OR52E8 | OR52H1 | OR52I1 | OR52I2 | OR52J3 | OR52K1 | OR52K2 | OR52K3P | OR52L1 | OR52M1 | OR52N1 | OR52N4 | OR52N5 | OR52R1 | OR52W1 | OR52Z1P | OR56A1 | OR56A3 | OR56A4 | OR56A5 | OR56B1 | OR56B4 | OR5A1 | OR5A2 | OR5AC1 | OR5AC2 | OR5AK2 | OR5AK4P | OR5AN1 | OR5AP2 | OR5AR1 | OR5AS1 | OR5AU1 | OR5B12 | OR5B17 | OR5B2 | OR5B21 | OR5B3 | OR5BA1P | OR5C1 | OR5D13 | OR5D14 | OR5D16 | OR5D17P | OR5D18 | OR5E1P | OR5F1 | OR5H1 | OR5H14 | OR5H15 | OR5H2 | OR5H4P | OR5H6 | OR5I1 | OR5K1 | OR5K2 | OR5K3 | OR5K4 | OR5L1 | OR5L2 | OR5M1 | OR5M10 | OR5M11 | OR5M3 | OR5M4P | OR5M8 | OR5M9 | OR5P1P | OR5P2 | OR5P3 | OR5T1 | OR5T2 | OR5T3 | OR5V1 | OR5W2 | OR6A2 | OR6B1 | OR6B2 | OR6B3 | OR6C1 | OR6C2 | OR6C3 | OR6C4 | OR6C65 | OR6C70 | OR6C74 | OR6C75 | OR6C76 | OR6F1 | OR6J1 | OR6K2 | OR6K3 | OR6M1 | OR6N1 | OR6N2 | OR6P1 | OR6Q1